

**Rhythm Biosciences Limited**  
**Appendix 4E**  
**Preliminary final report**

**1. Company details**

Name of entity:	Rhythm Biosciences Limited
ABN:	59 619 459 335
Reporting period:	For the year ended 30 June 2023
Previous period:	For the year ended 30 June 2022

---

**2. Results for announcement to the market**

		<b>2023</b>	<b>2022</b>
		<b>\$</b>	<b>\$</b>
Other income from ordinary activities	Up 36%	3,324,112	2,452,371
Loss from ordinary activities after tax attributable to the owners of Rhythm Biosciences Limited	Down 7% to	(8,217,557)	(8,793,521)
Comprehensive loss for the year attributable to the owners of Rhythm Biosciences Limited	Down 7% to	(8,217,557)	(8,793,521)

*Dividends*

There were no dividends paid, recommended or declared during the financial year.

*Comments*

The loss for the consolidated entity after providing for income tax was \$8,217,557. Comments on activities during the year are included in the Executive Chairman's Report in the Annual Report attached.

---

**3. Net tangible assets**

	<b>Reporting period</b>	<b>Previous period</b>
	<b>Cents</b>	<b>Cents</b>
Net tangible assets per ordinary security	<u>2.46</u>	<u>3.16</u>

---

**4. Control gained over entities**

In the United Kingdom, Rhythm Biosciences UK Limited, was incorporated on 23 June 2023 as a 100% owned subsidiary.

---

**5. Loss of control over entities**

Not applicable.

---

**6. Details of associates and joint venture entities**

Not applicable.

---

**Rhythm Biosciences Limited**  
**Appendix 4E**  
**Preliminary final report**

**7. Audit qualification or review**

*Details of audit/review dispute or qualification (if any):*

The financial statements have been audited and an unqualified opinion has been issued.

---

**8. Attachments**

*Details of attachments (if any):*

The Annual Report of Rhythm Biosciences Limited for the year ended 30 June 2023 is attached.

---

**9. Signed**

**For personal use only**  
  
Otto Buttula  
Executive Chairman

Date: 31 August 2023